Article

Ellex’s SLT technology launches in U.S.

Ellex Medical Lasers Ltd. announced that it has launched its proprietary selective laser trabeculoplasty (SLT) technology in the United States.

Adelaide, Australia-Ellex Medical Lasers Ltd. announced the launch of its proprietary selective laser trabeculoplasty (SLT) technology in the United States, with the official launch at this week's World Glaucoma Congress.

The launch comes following the expiration of a patent held by Massachusetts General Hospital (sub-licensed to Lumenis), which prevented Ellex from selling its SLT technology in the United States, the company said in a prepared statement.

SLT advanced laser therapy, which is non-invasive and non-thermal, stimulates a natural healing response in the eye to treat glaucoma.

“[SLT] also overcomes the compliance issues and side effects of anti-glaucoma medications, which have long plagued physicians and patients alike,” said Tom Spurling, chief executive officer of Ellex.

As a highly effective approach for first-line glaucoma treatment, SLT can also be used as an adjunct therapy with medications and as alternative therapy when medications or surgery fail. Ellex’s SLT technology platform is available in two product configurations: Tango SLT/YAG combination laser and Solo SLT laser.

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.